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Introduction
Enthesitis related arthritis (ERA) is a chronic inflamma-
tory disorder primarily affecting the axial skeleton as
well as peripheral joints and entheses. DMARD’s are
succesful in controling peripheral disease; however their
effectiveness is diminished when axial inflammation is
present. The use of anti tnfa medications in adult
patients with ankylosing spondylitis is well documented.
Nevertheless, data regarding their use in children with
the juvenile spondylarthritis(jspa) are missing.
Objectives
To assess the efficacy and safety of adalimumab, a fully
humanized anti-tnfa monoclonal antibody, as mono-
therapy in jspa/ERA.
Methods
16 patients (9 females,7 males;mean age:10 years) who met
the EULAR criteria for ERA and the ASAS criteria for AS
were enrolled. Following NSAID treatment failure, the
patients received 24 mg/m2 of adalimumab subcuta-
neously every 14 days for 12 months. Patients had MRI
proven sacroilitis, inflammatory lumbar pain(ILP) and
were HLA-B27 positive. Outcome measures were presence
of morning stiffness, duration of morning stiffness, CRP
measurement, pain assessment (based on 10 cm Visual
Analog Scale-VAS-) and physician assessment (based on
10 cm VAS). Mean time from diagnosis to initiation of
treatment was 4 months (range 3-7 months), while from
the onset of symptoms till the beginning treatment mean
time was 12 months (range 5-28 months). Patients were
reviewed at 3, 6, 9 and 12 months following initiation of
treatment and had repeat MRI scans at 3 and 9 months.
Results
At the beginning of the study all patients had ILP (mean
pain VAS:6.8 cm), morning stiffness with a mean duration
of 75 min and positive MRI findings. Mean physician VAS
was 4.6 cm and mean CRP was 69 mg/dl(range: 25-102
mg/dl). At three months the mean CRP was 18 mg/dl,
physician VAS was 1.9 cm, pain VAS 1.6 cm; morning
stiffness improved by 80% and 57% of patients showed
improved MRI findings. Reassessment at 6 months
showed improvement of morning stiffness (18%) and its
duration(9 min) as well as further improvement in mean
physician VAS(1.2 cm) and pain VAS(1 cm). At 9 months
mild further reduction in the prevalence(13%) and dura-
tion of morning stiffness(7 min) and improvement in phy-
sician VAS(0.5 cm) and pain VAS(0.7 cm) was recorded.
Mean CRP was 9 mg/dl. 19% of patients showed persistent
although improved MRI findings. The majority of these
children had bilateral sacroilitis in the beginning of the
study. At 12 months 8% had morning stiffness, and its
mean duration was unchanged(7 min). Mean pain and
physician VAS values were similar to those at nine months
(physician VAS0.3 cm, pain VAS 0.5 cm) Mild-moderate
adverse reactions were seen in 37%.
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Conclusion
This is a novel study in the pediatric population showing
that adalimumab monotherapy in early stages of jspa/ERA
is effective and safe. Adalimumab leads to early remission
as defined by reduction of pain and stiffness. Overall,
patient improvement is gradual and sustained. No further
improvement was noted beyond 9 months of treatment.
MRI findings show slower improvement; however 19% of
patients had radiological evidence of inflammation at nine
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